Bayer AG (BYR.L, BAYRY.PK, BAYZF.PK) said the European Commission has issued its go ahead for the approval of the company's subgroup Bayer HealthCare's new low-dose combined oral contraceptive Flexyess. Based on the European Commission's positive decision, the Health Authorities of the EU Member States will grant national approvals in the coming weeks.
Flexyess will be the first low-dose combined oral contraceptive approved in the EU member states for a flexible extended regimen, offering women the option of 'personal period planning', meaning they can choose both the number and timing of their periods according to their needs.
Dr. Flemming Ornskov, chief marketing officer at Bayer HealthCare's Pharmaceuticals division, said, "Once Flexyess is launched, women will have the convenience and flexibility to influence the timing of their periods according to their individual needs."
For comments and feedback: editorial@rttnews.com